Neuropace Statements
NP
Data from Neuropace`s earning releases including common size income statement and balance sheet.
Common size analysis evaluates financial statements by expressing each line item as a percentage of a base amount for that period.
Key Information:
Report currency:
USD - US dollar
Last reporting period:
30 Jun, 2024
Next reporting period:
28 Sep, 2024
Report frequency:
Quarterly
Earnings release date:
13 Aug, 2024
Expected release date:
—
Neuropace Income Statement
B
M
USD (except Earnings per share)
Financial
Revenue
Cost of sales
Gross profit
Research and development
Selling, general and administrative
Total operating expenses
Operating income
Interest expense
Other income
Income before tax
Provision for income taxes
Net income
Diluted earnings per share
Shares outstanding after dilution
19.256
6.2 %
100
5.122
26.6
14.134
5.9 %
73.4
6.065
31.5
14.299
74.3
20.364
-2.5 %
105.8
-6.23
17.4 %
-32.4
-1.404
-7.3
0.12
0.6
-7.514
15.8 %
-39.02
—
0
-7.514
15.8 %
-39.02
-0.26
28.853
18.124
0.6 %
100
4.781
26.4
13.343
-1.5 %
73.6
5.784
31.9
15.104
83.3
20.888
12.3 %
115.3
-7.545
-49.4 %
-41.6
-1.431
-7.9
0.051
0.3
-8.925
-44 %
-49.2
—
0
-8.925
-44 %
-49.2
-0.316
28.285
18.012
9.6 %
100
4.467
24.8
13.545
10.8 %
75.2
5.377
29.9
13.219
73.4
18.596
2.2 %
103.2
-5.051
15.1 %
-28.04
-1.414
-7.9
0.265
1.5
-6.2
14.6 %
-34.4
—
0
-6.2
14.6 %
-34.4
-0.231
26.81
16.43
-0.5 %
100
4.19
25.5
12.23
2.2 %
74.4
4.8
29.2
13.39
81.5
18.19
-8.2 %
110.7
-5.95
24.2 %
-36.2
-1.42
-8.6
0.12
0.7
-7.26
20.4 %
-44.2
—
0
-7.26
20.4 %
-44.2
-0.28
26.02
16.51
14.1 %
100
4.54
27.5
11.97
15.4 %
72.5
5.34
32.3
14.48
87.7
19.82
6 %
120
-7.85
5.6 %
-47.5
-1.39
-8.4
0.12
0.7
-9.12
12.1 %
-55.2
—
0
-9.12
12.1 %
-55.2
-0.36
25.47
14.47
13.1 %
100
4.1
28.3
10.37
17.8 %
71.7
5.26
36.4
13.43
92.8
18.69
0.2 %
129.2
-8.32
15.6 %
-57.5
-1.24
-8.6
-0.82
-5.7
-10.38
6.9 %
-71.7
—
0
-10.38
6.9 %
-71.7
-0.41
25.1
12.79
14.6 %
100
3.99
31.2
8.8
10.4 %
68.8
5.09
39.8
13.57
106.1
18.66
2.7 %
145.9
-9.86
3.3 %
-77.09
-1.14
-8.9
-0.15
-1.2
-11.15
5.4 %
-87.2
—
0
-11.15
5.4 %
-87.2
-0.45
24.83
11.16
9.4 %
100
3.19
28.6
7.97
6.7 %
71.4
5.61
50.3
12.55
112.5
18.17
-1.5 %
162.8
-10.2
7 %
-91.4
-1.48
-13.3
-0.1
-0.9
-11.79
7.1 %
-105.6
—
0
-11.79
7.1 %
-105.6
-0.48
24.73
10.2
-10.3 %
100
2.73
26.8
7.47
-9.6 %
73.2
5.67
55.6
12.77
125.2
18.44
2.3 %
180.8
-10.97
-12.4 %
-107.5
-1.63
-16
-0.09
-0.9
-12.69
-10.7 %
-124.4
—
0
-12.69
-10.7 %
-124.4
-0.52
24.5
11.37
3.4 %
100
3.12
27.4
8.26
2.2 %
72.6
5.58
49.1
12.44
109.4
18.02
5.4 %
158.5
-9.76
-8.2 %
-85.8
-1.7
-15
—
0
-11.46
-7.2 %
-100.8
—
0
-11.46
-7.2 %
-100.8
-0.47
24.31
11
6.4 %
100
2.92
26.5
8.08
7.6 %
73.5
5.35
48.6
11.75
106.8
17.09
24.3 %
155.4
-9.02
-44.6 %
-82
-1.41
-12.8
-0.26
-2.4
-10.69
-32.3 %
-97.2
—
0
-10.69
-32.3 %
-97.2
-0.44
24.25
10.34
-18.1 %
100
2.83
27.4
7.51
-19.8 %
72.6
4.33
41.9
9.42
91.1
13.75
-1.6 %
133
-6.24
-35.4 %
-60.3
-1.83
-17.7
-0.01
-0.1
-8.08
4.8 %
-78.1
—
0
-8.08
4.8 %
-78.1
-0.34
24.1
12.63
12.6 %
100
3.27
25.9
9.36
10.2 %
74.1
4.44
35.2
9.53
75.5
13.97
12.9 %
110.6
-4.61
-19.1 %
-36.5
-1.87
-14.8
-2.02
-16
-8.49
3.6 %
-67.2
—
0
-8.49
3.6 %
-67.2
-0.35
24.29
11.22
—
100
2.72
24.2
8.49
—
75.7
4.1
36.5
8.27
73.7
12.37
—
110.2
-3.87
—
-34.5
-1.85
-16.5
-3.09
-27.5
-8.81
—
-78.5
—
0
-8.81
—
-78.5
-0.38
23.14